Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
Key Highlights
- ➤BHV-1530 produced responses in 6 of 10 evaluable FGFR3-altered patients at ≥3.3 mg/kg
- ➤Urothelial cancer responses reached 3 of 5 patients after prior EV+P treatment
- ➤HPV-positive HNSCC responses reached all 3 evaluable patients
- ➤BHV-1530 showed no dose-limiting toxicities, treatment-related SAEs or deaths among 30 patients
- ➤Biohaven plans a pivotal urothelial-cancer study as early as 1H 2027 after FDA Type C meeting
Expert Statements
Gerald S. Falchook, M.D., Director of Sarah Cannon Research Institute at HCA HealthONE
“Many patients in this study had progressed on multiple prior therapies, including enfortumab vedotin plus pembrolizumab and FGFR inhibitors in urothelial cancer, so seeing durable responses is very encouraging.”
Gerald S. Falchook, M.D., Director of Sarah Cannon Research Institute at HCA HealthONE
“We also saw deep responses in HPV-positive head and neck cancer, where options after immunotherapy are limited. Importantly, BHV-1530 has been well tolerated, with no dose-limiting toxicities and none of the hyperphosphatemia, nail or retinal toxicities that often restrict FGFR tyrosine kinase inhibitor therapy.”
Nushmia Khokhar, M.D., Chief Medical Officer of Oncology at Biohaven
“Unlike FGFR tyrosine kinase inhibitors, which block kinase signaling inside the cell, BHV-1530 is an ADC designed to bind FGFR3 on the tumor cell surface, be internalized and release a potent topoisomerase I payload, independent of kinase-domain resistance mutations.”
Nushmia Khokhar, M.D., Chief Medical Officer of Oncology at Biohaven
“Following a recent Type C meeting with the FDA, we are excited to advance BHV-1530 into a pivotal study in FGFR3-altered tumors, beginning with urothelial cancer, as early as the first half of 2027, with the goal of supporting a potential accelerated approval.”
Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026 PR Newswire
Phase 1 data presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, showed deep and durable responses in patients with FGFR3-altered urothelial cancer (UC) and head and neck squamous cell carcinoma (HNSCC). As of the data cutoff in the ongoing study, 6 of 10 evaluable patients with FGFR3 activating alterations treated at doses of ≥3.3 mg/kg had responded, including 3 of 5 with UC and 3 of 3 with HPV-positive HNSCC.
Get started
Create a free account to read the full story.
